This suggests that the anti-tumor effects of disulfidptosis may involve immunomodulatory mechanisms, potentially through CD8+ T cell functional inhibition or SLC3A2/SLC7A11-mediated cystine metabolism regulation impacting immune escape in ESCC. The gene discussed is SLC3A2; the disease is esophageal squamous cell carcinoma.